Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
33.01 USD | -7.14% | -12.16% | +54.30% |
05-15 | Spyre Therapeutics, Inc. Announces Board Changes | CI |
05-13 | Wells Fargo Adjusts Price Target on Spyre Therapeutics to $40 From $35, Maintains Overweight Rating | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+54.30% | 1.43B | |
+11.10% | 115B | |
+12.57% | 106B | |
-4.11% | 24.69B | |
-2.33% | 21.97B | |
-6.03% | 19.27B | |
-13.13% | 17.56B | |
-40.50% | 17.32B | |
+6.48% | 14.03B | |
+32.09% | 12.13B |
- Stock Market
- Equities
- SYRE Stock
- News Spyre Therapeutics, Inc.
- Transcript : Aeglea BioTherapeutics, Inc. - Shareholder/Analyst Call